![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 06, 2020 10:37:47 AM
Nuvilex Associate’s Patent Expansion Sets Stage for Treatment of HIV, Ebola, and SARS Virus
December 22, 2011 10:06 AM Eastern Standard Time
SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions including encapsulation of live cells and services through their associate SG Austria, released information today about the therapeutic potential of the patent for treatment of HIV and Ebola viruses, Bird flu, SARS, and other infectious diseases.
This patent family provides for encapsulation and implantation of live cells producing proteins to treat specific diseases. Once implanted, live cells provide continuous production of the therapeutic protein needed, like antibodies or antibody-like molecules.
Substantial research has shown that the ability to have continuous production in the body avoids the rise and fall associated with standard injections, making this a commanding delivery method for treating many different diseases. The power of the use of the technology has already been demonstrated in a therapeutic animal model setting where production of a neutralising antibody led to protection against a lethal virus-induced disease, even when the infection was full-blown prior to treatment.
Nuvilex believes such diseases as diverse as HIV, Ebola, and other infectious or viral diseases are excellent candidates for such treatment.
For infectious diseases such as HIV, Ebola, West Nile, or the SARS virus, for which neutralizing already antibodies exist, even sudden-onset, life-threatening conditions have great potential for rapid and long-term treatment using encapsulation technology.
Anti-HIV neutralizing antibodies have been isolated by a number of researchers and two of these, b12 and VRC01, have recently been reported to completely protect against HIV in an animal model. The long term production of such antibodies from a depot of encapsulated live cells may improve the efficacy of such treatments.
Moreover, recent application of the cell encapsulation technology may prove to have a useful role for the treatment of life-threatening Bird flu (avian influenza) infections caused by the H5N1 influenza A virus that primarily infects birds, including poultry. Research since the highly publicized Bird flu outbreaks showed antibodies can neutralize the effects of the Avian influenza virus, making it another excellent encapsulation candidate.
Dr. Robert F. Ryan, President and CEO, commented, “The revenue potential from this family of patents is substantial. We have asked our analysts to establish a valuation for this family of patents, which we will disseminate to the investment community. We believe the ability to produce encapsulated cells producing proteins or antibodies to be a valuable asset for Nuvilex and should allow our larger new Nuvilex to expand our capabilities in the New Year. We are already working on this area and hope to move it forward farther in the coming year for diseases like HIV, Ebola virus, bird flu, and SARS.”
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM